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Abstract
UK Biobank is among the world’s largest repositories for phenotypic and genotypic information in 
individuals of European ancestry1. We performed a genome-wide association study in UK 
Biobank testing ~9 million DNA sequence variants for association with coronary artery disease 
(4,831 cases; 115,455 controls) and carried out meta-analysis with previously published results. 
We identified fifteen novel loci, bringing the total number of coronary artery disease-associated 
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loci to 95. Phenome-wide association scanning revealed that CCDC92 likely affects coronary 
artery disease through insulin resistance pathways whereas experimental analysis suggests that 
ARHGEF26 impacts the transendothelial migration of leukocytes.
Journal Subject Codes
coronary artery disease; population genetics; genome-wide association studies; gene-expression
Coronary artery disease (CAD) is a leading cause of disability and mortality worldwide2. 
Genome-wide association studies (GWAS) have provided new clues to the pathophysiology 
for this common, complex disease. Largely using a case-control design with cases 
ascertained based on CAD status, published studies have highlighted at least 80 loci 
reaching genome-wide significance3–9.
Population-based biobanks such as UK Biobank offer new potential for genetic analysis of 
common complex diseases. New opportunities include scale, a diverse range of traits, and 
the ability to explore a fuller spectrum of phenotypic consequences for identified DNA 
variants. Leveraging the UK Biobank resource, we sought to: 1) perform a genetic discovery 
analysis; 2) explore the phenotypic consequences and tissue-specific effects associated with 
CAD risk alleles; and 3) characterize the functional consequences of a risk mutation in a 
promising pathway.
We designed a three-stage GWAS (Fig. 1). In Stage 1, we tested the association of DNA 
sequence variants with CAD in UK Biobank. In Stage 2 we took forward 2,190 variants that 
reached nominal significance in Stage 1 (P<0.05) for meta-analysis with results from an 
exome-focused-array analysis in 42,355 cases and 78,240 controls6. In Stage 3, we took 
forward 387,174 variants that reached nominal significance in Stage 1 and not tested in 
Stage 2 for meta-analysis with results from a genome-wide imputation study in 60,801 cases 
and 123,504 controls5. For each variant, we combined statistical evidence across Stages 1 
and 2 (or Stages 1 and 3) and set a statistical threshold of P < 5 ×10−8 for genome-wide 
significance.
Characteristics of UK Biobank participants stratified by presence of CAD are presented in 
Supplementary Table 1. CAD cases were more likely to be older, male, on lipid-lowering 
therapy, have a history of smoking, and affected with type 2 diabetes. After quality control, 
9,061,845 DNA sequence variants were tested for association in 4,831 CAD patients and 
115,455 controls in UK Biobank (Stage 1). A total of 269 variants at five distinct loci met 
the genome-wide significance threshold (P < 5×10−8) (Supplementary Fig. 1 and 2). All five 
have been previously reported5,10–13. In UK Biobank, the 9p21/CDKN2B-AS1 variant 
rs4977575 (NC_000009.12:g.22124745C>G) was the top association result (49% frequency 
for G allele; OR =1.24; 95%CI: 1.19–1.29; P = 5.40×10−23); the other four loci were 1p13/
SORT1, PHACTR1, LPA, and KCNE2 (Supplementary Table 2). For a set of previously 
reported CAD loci5, we compared the effect estimates from the published literature with that 
from the current analysis in UK Biobank and found strong positive correlation in effect sizes 
(β = 0.92, 95%CI: 0.77–1.06; P = 1.8×10−17, Supplementary Fig. 3); these results validate 
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our CAD phenotype definition in UK Biobank. A total of 513,403 variants exceeded 
nominal significance (P < 0.05) and were taken forward to Stages 2 or 3.
After meta-analysis, 15 new loci exceeded genome-wide significance (Tables 1–2), bringing 
the total number of established CAD loci to 95. Of note, while this manuscript was under 
review, one of the 15 loci (HNF1A) has since been reported9. Effect allele frequencies of the 
15 newly identified loci ranged from 13% to 86%, with effect sizes ranging from 1.05 to 
1.08. Descriptions of relevant loci appear in Supplementary Table 3, and regional association 
plots for novel CAD loci are shown in Supplementary Figures 4–6.
To move from these 15 DNA sequence variants to biologic insights, we took two 
approaches: phenome-wide association scanning and functional analysis. Understanding the 
full spectrum of phenotypic consequences of a given DNA sequence variant may shed light 
on the mechanism by which a variant/gene leads to disease. Termed a ‘phenome-wide 
association study’ or “PheWAS”, this approach tests the association of a mapped disease 
variant with a broad range of human phenotypes14. In collaboration with Genomics plc, we 
conducted a PheWAS combining UK Biobank data, mRNA transcript phenotypes in the 
Genotype-Tissue Expression Project (GTEx) dataset15, and an integrated set of GWAS 
results from a variety of publically available sources16–24.
We found that several of the newly identified DNA sequence variants correlated with a range 
of human traits (Fig. 2, Supplementary Tables 4–5). For example, the intronic variant 
rs10841443 within RP11-664H17.1 is in close proximity to PDE3A, a phosphodiesterase 
previously implicated in an autosomal dominant form of hypertension25. PheWAS showed 
an association for this variant with diastolic blood pressure26, suggesting that this locus may 
be acting through hypertension. The variant rs2244608 within HNF1A has been previously 
associated with LDL cholesterol, a causal path to atherosclerosis16. The variant rs7500448 
within CDH13 (encoding Cadherin 13 or T-Cadherin), a vascular adiponectin receptor 
implicated in hypertensive and insulin resistance biology27, associates with plasma 
adiponectin levels. Variant rs2972146 is downstream of IRS1 (encoding the insulin receptor 
substrate-1 gene24) and is a cis-eQTL for IRS1 expression in adipose tissue. rs2972146 
associates with a range of phenotypes seen in the setting of insulin resistance including HDL 
cholesterol, triglycerides, adiponectin, fasting insulin, and type 2 diabetes.
Compelling additional insights from the PheWAS emerged at the CCDC92 locus. Across 25 
distinct traits and disorders, we observed significant associations (P < 0.00013) for CCDC92 
p.Ser70Cys (rs11057401) with body fat percentage, waist-to-hip circumference ratio, as well 
as plasma high-density lipoprotein, triglyceride, and adiponectin levels. The directionality of 
these associations are hallmarks of insulin resistance and lipodystrophy17,28, and the 
association with plasma adiponectin levels localizes these genetic effects to adipose tissue. 
Recent work has highlighted two candidate genes at this locus, CCDC92 and DNAH1029, 
and further experimental work is necessary to define the causal gene at this locus.
However, a few of the CAD loci (FN1, LOX, ITGB5, and ARHGEF26) did not associate 
with any of the studied risk factor traits and thus, appear to function through pathways 
beyond known CAD risk factors (Fig. 2, Supplementary Tables 4–5). A common variant 
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within an intron of FN130 (encoding Fibronectin 1) and a missense variant in LOX31 
(encoding Lysyl Oxidase) suggest potential links to extracellular matrix biology. Of note, 
rare coding mutations in LOX were recently described to cause Mendelian forms of thoracic 
aortic aneurysm and dissection32,33, highlighting a potential common link between 
atherosclerosis and aortic disease, possibly through altered extracellular matrix biology. A 
variant downstream of ITGB534 (encoding Integrin Subunit Beta 5) suggests pathways 
underlying cell adhesion and migration.
In aggregate, our analysis brings the total number of known CAD loci to 953–9, and in 
Figure 3, we organize these loci into plausible pathways. Of note, the causal variant, gene, 
cell type, and mechanism has been definitively identified at only a few of these loci and as 
such, additional experimental research will be required, particularly at >50% of loci without 
an apparent link to known risk factors.
At one of the new loci that did not relate to known risk factors, ARHGEF26 (encoding Rho 
Guanine Nucleotide Exchange Factor 26), we performed functional studies. Prior 
experimental work had connected this gene with murine atherosclerosis35. Earlier studies 
established a role for ARHGEF26 in facilitating the transendothelial migration of 
leukocytes, a key step in the initiation of atherosclerosis36,37. ARHGEF26 has been shown 
to activate RhoG GTPase by promoting the exchange of GDP by GTP and contributing to 
the formation of ICAM-1-induced endothelial docking structures that facilitate leukocyte 
transendothelial migration 36,37. In addition, Arhgef26 −/− mice, when crossed with 
atherosclerosis-prone Apoe null mice, displayed less aortic atherosclerosis35.
At ARHGEF26 p.Val29Leu (rs12493885), the 29Leu allele, observed in 85% of participants, 
is associated with increased risk for CAD. We first examined the hypothesis that a haplotype 
block containing this variant may alter expression of ARHGEF26 in coronary artery. While 
this region demonstrates eQTL effects in a variety of tissues, there is no evidence of 
alteration of ARHGEF26 expression in coronary artery in both eQTL and allele specific 
expression analyses (Supplementary Fig. 7). To further evaluate the possibility that a 
haplotype containing the 29Leu allele may affect gene expression, we performed a luciferase 
reporter assay. We cloned a 2.5 kb region immediately upstream of the ARHGEF26 start 
codon consisting of the promoter, 5′ untranslated region (5′ UTR), and regions with 
ENCODE annotations suggestive of potential cis-acting elements. We obtained the reference 
(in LD with Val29 G allele) and alternative (in LD with 29Leu C allele) haplotypes of this 
region from human rs12493885 heterozygotes. We coupled each haplotype with a luciferase 
reporter, and measured luciferase activity (Supplementary Fig. 8). In HEK293, human aortic 
endothelial cells (HAEC), and human umbilical vein endothelial cells (HUVEC), there is no 
significant difference in luciferase activity between reference and alternative haplotypes. 
These data suggest that the ARHGEF26 29Leu allele may confer CAD risk via mechanisms 
other than affecting ARHGEF26 transcription or promoter activity in disease-relevant tissue.
Next, we examined the hypothesis that ARHGEF26 p.Val29Leu may influence disease risk 
through its protein-altering consequence. We knocked down endogenous ARHGEF26 
through siRNA and observed decreased leukocyte transendothelial migration, leukocyte 
adhesion on endothelial cells, and vascular smooth cell proliferation38 (Fig. 4, 
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Supplementary Fig. 9). Overexpression of exogenous, wild-type ARHGEF26 rescued these 
phenotypes. However, ARHGEF26 29Leu mutant overexpression led to rescued phenotypes 
that consistently exceeded wild-type. These data support the hypothesis that the ARHGEF26 
29Leu allele associated with increased CAD risk may lead to a gain-of-function ARHGEF26 
protein.
How could the ARHGEF26 29Leu mutation lead to a gain-of-function phenotype? We 
evaluated its functional impact in two ways, addressing ARHGEF26 quality and quantity, 
respectively. First, could the 29Leu mutation alter ARHGEF26 nucleotide exchange activity 
on RhoG? To answer this question, we developed a GTP-GDP nucleotide exchange assay 
using recombinant human full-length ARHGEF26 (wild-type or 29Leu) and RhoG 
proteins39. In a cell-free system, equal amount of wild-type or 29Leu ARHGEF26 protein 
was incubated with RhoG pre-loaded with GDP. After 60 minutes, we observed no 
significant difference in nucleotide exchange activity between wild-type and 29Leu mutant 
ARHGEF26 (Supplementary Fig. 10).
Second, could the 29Leu allele affect cellular abundance of ARHGEF26 protein? We 
examined this possibility by treating cells expressing wild-type or 29Leu mutant 
ARHGEF26 with cycloheximide, a protein synthesis inhibitor, and compared ARHGEF26 
degradation over time by Western blotting. Compared to wild-type ARHGEF26, the 29Leu 
mutant protein displayed a longer half-life (Supplementary Fig. 11). While further work is 
needed to understand the mechanism in vivo, in vitro results suggest that the gain of function 
phenotype observed may be secondary to the 29Leu mutant protein’s resistance to 
degradation.
Our study should be interpreted within the context of its limitations. First, we focused on 
participants of European ancestry within UK Biobank and therefore results may not be 
generalizable to other populations. Second, our CAD phenotype definitions are based largely 
on interview and electronic health records and this may result in misclassification of case 
status. However, such misclassification should reduce statistical power for discovery and 
bias results toward the null. Finally, although we observed no evidence of robust changes in 
ARHGEF26 expression associated with the 29Leu haplotype in disease relevant tissue, it is 
possible that other regulatory mechanisms may potentiate the gain of function phenotypes 
we observed.
In summary, we performed a gene discovery study for CAD using a large population-based 
biobank, identified 15 new loci, and explored the phenotypic consequences of CAD risk 
variants through PheWAS and in vitro functional analysis. These findings permit several 
conclusions. First, CAD cases phenotyped via electronic health records and verbal 
interviews exhibit similar genetic architecture to those derived in epidemiologic cohorts and 
can prove useful in gene discovery efforts. Second, phenome-wide association studies with 
risk variants can provide initial clues on how DNA sequence variants may lead to disease. 
Lastly, considerable experimental evidence in cells and rodents has suggested that 
transendothelial migration of leukocytes is a key step in the formation of atherosclerosis40; 
here, we provide human genetic support for a role of this pathway in CAD.
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Online Methods
Study Design and Samples
We performed a three-stage sequential analysis to identify novel genetic loci associated with 
CAD. In Stage 1, we first tested the association of DNA sequence variants with CAD in UK 
Biobank. Beginning in 2006, individuals aged 45 to 69 years old were recruited from across 
the United Kingdom for participation in the UK Biobank Study1. At enrollment, a trained 
healthcare provider ascertained participants’ medical histories through verbal interview. In 
addition, participants’ electronic health records (EHR) including inpatient International 
Classification of Disease (ICD-10) diagnosis codes and Office of Population and Censuses 
Surveys (OPCS-4) procedure codes, were integrated into UK Biobank. Individuals were 
defined as having CAD based on at least one of the following criteria:
1. Myocardial infarction (MI), coronary artery bypass grafting, or coronary artery 
angioplasty documented in medical history at time of enrollment by a trained 
nurse
2. Hospitalization for ICD-10 code for acute myocardial infarction (I21.0, I21.1, 
I21.2, I21.4, I21.9)
3. Hospitalization for OPCS-4 coded procedure: coronary artery bypass grafting 
(K40.1–40.4, K41.1–41.4, K45.1–45.5)
4. Hospitalization for OPCS-4 coded procedure: coronary angioplasty with or 
without stenting (K49.1–49.2, K49.8–49.9, K50.2, K75.1–75.4, K75.8–75.9)
All other individuals were defined as controls. In total, genotypes were available for 120,286 
participants of European ancestry.
In Stage 2, we took forward 2,190 variants that reached nominal significance in Stage 1 for 
meta-analysis in the Coronary ARtery DIsease Genome wide Replication and Meta-analysis 
(CARDIoGRAM) Exome Consortia exome array analysis which incorporated 42,355 cases 
and 78,240 controls6 (Supplementary Table 6). In Stage 3, we took forward 387,174 variants 
that reached nominal significance in Stage 1 (and not available in Stage 2) for meta-analysis 
into the CARDIoGRAMplusC4D 1000 Genomes imputation study containing 60,801 cases 
and 123,504 controls5. Informed consent was obtained for all participants, and UK Biobank 
received ethical approval from the Research Ethics Committee (reference number 11/NW/
0382). Our study was approved by a local Institutional Review Board at Partners Healthcare 
(protocol 2013P001840).
Genotyping and Quality Control
UK Biobank samples were genotyped using either the UK Bileve42 or UK Biobank Axiom 
Arrays having been performed in 33 separate batches of samples by Affymetrix (High 
Wycombe, UK). A total of 806,466 directly genotyped DNA sequence variants were 
available after variant quality control (QC). The UK Biobank team then performed 
imputation from a combined 1000 Genomes/UK10K reference panel; phasing was 
performed using SHAPEIT-3 and imputation carried out via IMPUTE3. Variant level QC 
exclusion metrics applied to imputed data for GWAS included: call rate < 95%, Hardy-
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Weinberg Equilibrium P-value <1×10−6, posterior call probability < 0.9, imputation quality 
<0.4, and minor allele frequency (MAF) < 0.005. Sex chromosome and mitochondrial 
genetic data were excluded from this analysis. In total, 9,061,845 imputed DNA sequence 
variants were included in our analysis. For sample QC, the UK Biobank analysis team 
removed individuals of relatedness 3rd degree or higher, and an additional 480 samples with 
an excess of missing genotype calls or more heterozygosity than expected were excluded. In 
total, genotypes were available for 120,286 participants of European ancestry.
Statistical Analysis
Stage 1 Association Analysis—The BOLT-LMM software43 was used to perform 
linear mixed models (LMMs) for association testing. CAD case status was analyzed while 
adjusting for age, gender, and chip array at run-time. This analysis was used to derive 
statistical significance. As effect estimates from BOLT-LMM software are unreliable due to 
the treatment of binary phenotype data as quantitative data, we performed logistic regression 
to derive effect estimates for each variant that exceeded genome-wide significance. Effect 
estimates of top variants were derived from logistic regression using allelic dosages 
adjusting for age, sex, chip at run-time, and ten principal components under the assumption 
of additive effects utilizing the R v3.2.0 and SNPTEST statistical software programs.
Stage 2 and 3 Meta-Analysis—In stage 2, top variants (P < 0.05) from UK Biobank 
were then meta-analyzed with exome chip data from the CARDIoGRAM Exome 
Consortium6. Tested variants in the CARDIoGRAM exome array study were analyzed 
through logistic regression with an additive model adjusting for study specific covariates and 
principal components of ancestry as appropriate. Top variants from UK Biobank that were 
not available for analysis in the CARDIoGRAM exome array study were then meta-
analyzed with data from the 1000 Genomes imputed CARDIoGRAMplusC4D GWAS5 in 
Stage 3.
Given differences in effect size units between the UK Biobank Stage 1 data and the 
CARDIoGRAM Exome/1000 Genomes CARDIoGRAMplusC4D data, both Stage 2 and 3 
meta-analyses were performed via a weighted z-score method, adjusting for an unbalanced 
ratio of cases to controls. To derive effect size estimates for variants exceeding genome-wide 
significance, we meta-analyzed logistic regression results using inverse-variance weighting 
with fixed effects (METAL software)44. We set a combined statistical threshold of P < 
5×10−8 for genome wide significance. P values reported in analysis Stages 1, 2, and 3 are all 
two-sided.
Phenome-Wide Association Study
For all 15 novel DNA sequence variants associated with CAD in our study, we collaborated 
with Genomics plc to conduct a phenome-wide association study. This PheWAS used the 
Genomics plc Platform, UK Biobank, and GTEx Consortium eQTL data. The Genomics plc 
Platform includes PheWAS data across 545 distinct molecular and disease phenotypes, at an 
integrated set of over 14 million common variants, from 677 GWAS studies. UK Biobank 
analyses within the Genomics plc Platform were conducted under a separate research 
agreement. We selected 25 phenotypes across a range of relevant diseases, metabolic and 
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anthropometric traits from either previously published GWAS datasets or UK Biobank. 
Complete details of phenotype definitions, sample sizes, and GWAS data sources are shown 
in Supplementary Tables 7 and 8. In the PheWAS, quantitative traits were standardized to 
have unit variance, imputation was performed to generate results for all variants within the 
1000 Genomes reference panel, and P values were recalculated based on a Wald test statistic 
for uniformity.
Phenotypes were declared to be significantly associated with the risk variant if they met a 
Bonferroni corrected P value of < 0.00013 [0.05/(25 traits × 15 DNA sequence variants)]. 
Phenome scan results were then depicted in a heatmap based on the Z-scores for all variant-
disease/trait associations aligned to the CAD risk allele as implemented by the gplots 
package in R v3.2.0. To identify loci that might influence gene expression, we used 
previously published cis-expression quantitative trait locus (eQTL) mapping data from the 
Genotype-Tissue Expression (GTEx) Consortium Project across 44 tissues15. We queried the 
15 novel variants identified in our study for overlap with genome-wide significant variant-
gene pairs from the GTEx portal.
Allele Specific Expression Analysis
Allele-specific expression (ASE) data from the GTEx project were obtained from dbGaP 
(accession phs000424.v6.p1). The generation of these data is summarized in Aguet et al., 
and relied on methods described earlier45. In brief, only uniquely mapping reads with base 
quality ≥ 10 at the SNP were counted, and only SNPs with coverage of at least 8 reads were 
reported. For ARHGEF26 p.Val29Leu, ASE counts were available for 20 heterozygous 
individuals. A two-sided binomial test was used to identify SNPs with significant allelic 
imbalance in each individual, and Benjamini-Hochberg adjusted p-values were calculated 
across all sites measured in an individual.
Luciferase Reporter Assay
HUVEC heterozygous for rs12493885 were identified from Caucasian donors by SNP 
genotyping. A 2.9 kb genomic fragment spanning from 5′ upstream of ARHGEF26 to exon 
2 (rs12493885) was cloned into a pMiniT 2.0 vector (NEB) using the heterozygous HUVEC 
genomic DNA as a template, and sequenced for reference and alternative alleles. The −2516 
to +2 reference and alternative haplotypes upstream of ARHGEF26 
(NC_000003.12:154119477-154121994) were amplified from the 2.9 kb region by PCR 
with primers designed to create 5′ NheI and 3′ HindIII restriction sites in the PCR 
products. The amplified fragments were subcloned between the NheI and HindIII sites of a 
promoterless firefly luciferase (luc2) expression vector pGL4.10 (Promega), to create two 
plasmids: pGL4.10-Ref and pGL4.10-Alt. Promoterless pGL4.10-control, and 
pGL4.73[hRluc/SV40] vector containing the renilla luciferase hRluc reporter gene and an 
SV40 early enhancer/promoter, were used as negative control and co-reporter, respectively. 
Cells were cotransfected with equal amounts of luc2 expression plasmid (pGL4.10-control, 
pGL4.10-Ref and pGL4.10-Alt) and pGL4.73 vector by Lipofectamine 2000. Cells were 
harvested at 48 h after transfection and followed by a Dual-Glo Luciferase Assay (Promega) 
to measure firefly and renilla luciferase activities. The firefly luciferase activity was 
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normalized to renilla luciferase in the same sample, and expressed as fold change relative to 
pGL4.10-control group.
Nucleotide Exchange Assay
Human full-length ARHGEF26 (wild-type or 29Leu) and RhoG (residues 1–188) proteins, 
both with N-terminal His-SUMO tags, were expressed in E. coli BL21(DE3) cells in TB 
media. Nucleotide exchange assay samples were prepared in buffer containing 10mM 
HEPES pH 7.4, 150mM NaCl, 1mM MgCl2, 0.5uM MANT-GTP, 2mM TCEP with 1μM 
ARHGEF26. Just prior to reading, RhoG protein, pre-loaded with GDP, was added to a final 
concentration of 0.4μM. MANT-GTP fluorescence was monitored for 60 minutes on a 
SpectraMax M2 at 37°C using an excitation wavelength of 280nm and an emissions 
wavelength of 440nm with a 435nm cutoff. Fluorescence data was imported into Prism 
GraphPad for analysis.
Functional Characterization of ARHGEF26 p.Val29Leu in Arterial Tissue
To investigate the functional effects of ARHGEF26 p.Val29Leu (rs12493885), we knocked-
down the expression of endogenous ARHGEF26 in cultured human aortic endothelial cells 
(HAEC) and human coronary artery smooth muscle cells (HCASMC) by RNA interference. 
We then overexpressed wild-type or mutant ARHGEF26 (29Leu) resistant to siRNA, and 
measured leukocyte transendothelial migration, leukocyte adhesion on endothelial cells, and 
HCASMC proliferation in vitro. We also evaluated the degradation of wild-type or 29Leu 
mutant ARHGEF26 with a cycloheximide chase assay and Western blotting. Additional 
details on experimental techniques are described in the Supplementary Note.
Data Availability
Stage 2 and Stage 3 data contributed by CARDIoGRAM Exome and 
CARDIoGRAMplusC4D investigators is available online (see URLs). The genetic and 
phenotypic UK Biobank data are available upon application to the UK Biobank. Genotype-
Tissue Expression Project data is available online.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study Design
Stage 1 consisted of a genome-wide association study for the coronary artery disease 
phenotype performed in UK Biobank; variants below a threshold P value < 0.05 moving 
forward to meta-analysis with CARDIoGRAM Exome (Stage 2) or 
CARDIoGRAMplusC4D summary statistics (Stage 3).
Abbreviations: 1000G, 1000 Genomes; CARDIoGRAMplusC4D, Coronary ARtery DIsease 
Genome-wide Replication and Meta-analysis
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Figure 2. Phenome-wide association results for 15 novel loci
For the 15 novel CAD risk variants identified in our study, Z-scores (aligned to the CAD risk 
allele) were obtained from the Genomics plc Platform and UK Biobank. A positive Z-score 
(red) indicates a positive association between the CAD risk allele and the disease/trait, while 
a negative Z-score (blue) indicates an inverse association. Boxes are outlined in green if the 
variant is significantly (P < 0.00013) associated with the given trait.
Abbreviations: Adj, Adjusted; BMI, Body Mass Index; BP, Blood Pressure; crea, Creatinine; 
cys, cystatin-c; COPD, chronic obstructive pulmonary disease; eGFR, estimated Glomerular 
Filtration Rate; HDL, High Density Lipoprotein; LDL, Low Density Lipoprotein;
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Figure 3. Biological pathways underlying genetic loci associated with coronary artery disease
CAD GWAS loci identified to date are depicted along with the plausible relationship to the 
underling biological pathway. The 15 new loci described in this paper are shown in bold. 
Loci names are based on the nearest genes; however, the causal gene(s) remains unclear for 
most associated loci and as such, the resultant annotation may prove incorrect in some cases. 
Adapted from Ref. 41.
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Figure 4. Functional assessment of ARHGEF26 p.Val29Leu in vitro
a) ARHGEF26-29Leu increases leukocyte transendothelial migration. HAEC were 
transfected with non-targeting siRNA and empty vector (control), siRNA against 
ARHGEF26 3′-UTR and empty vector, siRNA and ARHGEF26-WT, or siRNA and 
ARHGEF26-29Leu. Transfected HAEC were plated on transwell inserts and treated with 10 
ng/mL TNF-α. Differentiated HL60 cells were loaded on the upper chambers of transwells 
and allowed to transmigrate across HAEC towards vehicle (blue) or 50 ng/mL SDF-1 (red). 
The migrated cells were quantified as percentage of input cells per well (n=5 or 6; mean
±s.d.; F=11.89, DF=3 by two-way ANOVA within vehicle and SDF-1 subgroups with 
Fisher’s LSD test; variance among vehicle subgroups non-significant; NS, not significant; 
representative of 3 independent experiments).
b) ARHGEF26-29Leu increases leukocyte adhesion on endothelial cells. HAEC were 
transfected as 2a) and cultured on 96-well plates until confluent and treated with 10 ng/mL 
TNF-α. Calcein-AM-labeled THP-1 cells were incubated with HAEC and washed to remove 
non-adherent cells. The adherent cells were lysed, quantified by Calcein-AM fluorescence 
and compared to siRNA+WT (n=25, 17, 20, and 17; mean±s.d.; F=14.53, DF=3 by one-way 
ANOVA; NS, not significant; * P<0.0001 compared to siRNA+WT; representative of 3 
independent experiments).
c) ARHGEF26-29Leu increases vascular smooth muscle cell proliferation. HCASMC were 
transfected as 2a) and made quiescent by serum starvation for 48 h, followed by 72-h 
proliferation in normal serum medium. Cell proliferation was quantified by a luminescent 
assay and compared to siRNA+WT (n=20; mean±s.d.; F=197.5, DF=3 by one-way ANOVA; 
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NS, not significant; * P<0.0001 compared to siRNA+WT; representative of 3 independent 
experiments).
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